Posted by Michael Wonder on 03 Sep 2021
Heart failure med Jardiance scores MHRA approval
2 September 2021 - Eli Lilly and Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) has scored approval from the UK MHRA for the treatment of heart failure with reduced ejection fraction.
The marketing authorisation is based on results from Lilly/Boehringer’s EMPEROR-Reduced trial, which investigated the safety and efficacy of Jardiance in patients with chronic heart failure with reduced ejection fraction.
